Rockefeller Capital Management
OCUL icon

Rockefeller Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Rockefeller Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.2K Sell
3,181
-2,776
-47% -$25.2K ﹤0.01% 3574
2026
Q1 		$50.5K Buy
5,957
+3,385
+132% +$32.3K ﹤0.01% 3270
2025
Q4 		$31.2K Buy
+2,572
New +$31.2K ﹤0.01% 3288

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rockefeller Capital Management's OCUL Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Ocular Therapeutix (OCUL) stake by 47% in Q2 2026, selling an estimated $25.2K and leaving 3,181 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

Rockefeller Capital Management first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. The position peaked at $50.5K in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Rockefeller Capital Management held 3,181 shares of Ocular Therapeutix worth $31.2K as of Q2 2026.
  • Rockefeller Capital Management sold 2,776 Ocular Therapeutix shares in Q2 2026, an estimated $25.2K.
  • Ocular Therapeutix made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3574 holding.
  • Rockefeller Capital Management first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Ocular Therapeutix position peaked at $50.5K in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.